Send to

Choose Destination
BAOJ Pharm Sci. 2015;1(1). pii: 002. Epub 2015 Mar 3.

A Lanthanum-Tagged Chemotherapeutic Agent HA-Pt to Track the In Vivo Distribution of Hyaluronic Acid Complexes.

Author information

Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, USA.
HylaPharm LLC, Lawrence, KS.
Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS, USA.
Contributed equally


Hyaluronic acid drug conjugates can target anti-cancer drugs directly to tumor tissue for loco-regional treatment with enhanced bioavailability, local efficacy and reduced toxicity. In this study, the distribution and pharmacokinetics of hyaluronic acid carrier and a conjugated cisplatin anti-cancer drug were tracked by lanthanum (III) [La(III)] affinity tagging of the nanocarrier. The strong binding affinity of La(III) to HA enabled the simple preparation of a physiologically stable complex HA-Pt-La and straightforward simultaneous detection of HA-La and Pt in biological matrices using inductively coupled plasma-mass spectrometry (ICP-MS). Consequently, after subcutaneous injection of HA-Pt-La nanoparticles in human head and neck squamous cell carcinoma (HNSCC) tumor-bearing mice, the HA and Pt content were detected and quantified simultaneously in the plasma, primary tumor, liver and spleen.


Biodistribution; Human head and neck squamous cell carcinoma; Hyaluronic acid; Lanthanum


Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center